Click the play button below for an interview with Raj Iyer at InformexCompany ProfilePharmaceutical product development and commercialization is a highly expensive and lengthy process. Arch Pharmalabs Limited (Mumbai, India) provides the global drug industry with a powerful competitive edge through innovative, quality-focused, timely and cost-advantaged process R&D and manufacturing solutions across branded and generic product life cycles. The Company has a state of the art R&D centre, twelve GMP and ISO-certified sites (including US FDA and EDQM-inspected facilities) and 2,000 people in India. Maintaining a unique position as a non-competing supplier, Arch Pharmalabs? customer-centric service and product offering includes: Process R&D, exclusive synthesis of drug intermediates and active ingredients to enable pre-clinical studies, Phase I-III clinical trials, validation / launch planning and life cycle management for global innovators. Manufacture and supply of a wide range of generic APIs and intermediates for a worldwide client base. A key component of Arch Pharmalabs' growth strategy is to access superior chemical technologies through strategic alliances to help its customers develop newer, better and value-enhanced products. The Company rigorously follows global intellectual property standards, consistent with the WTO TRIPS agreement. Since its inception in 1997, Arch Pharmalabs has experienced robust financial growth, while exceeding its customers' expectations of quality and delivery. Exports constitute nearly 70% of the Company's annual revenues of approximately USD 130 million. Arch Pharmalabs USA Inc. is the company's US subsidiary and spearheads strategic alliance, commercial and marketing initiatives in North America.